Cargando…

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

Finding an effective treatment strategy for rheumatoid arthritis (RA) patients who have not benefited from previous tumor necrosis factor–α antagonist treatment is important for minimizing RA disease activity and improving patient outcomes. The aim of this study was to compare the safety and effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koike, Takao, Harigai, Masayoshi, Inokuma, Shigeko, Ishiguro, Naoki, Ryu, Junnosuke, Takeuchi, Tsutomu, Tanaka, Yoshiya, Yamanaka, Hisashi, Fujii, Koichi, Yoshinaga, Takunari, Freundlich, Bruce, Suzukawa, Michio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364424/ https://www.ncbi.nlm.nih.gov/pubmed/21331576 http://dx.doi.org/10.1007/s00296-011-1807-0

Ejemplares similares

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Shared epitope and rheumatoid arthritis severity: association with infliximab treatment in a postmarketing study
por: Marotte, H, et al.
Publicado: (2003)

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
por: Takeuchi, Tsutomu, et al.
Publicado: (2009)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Guidelines for the proper use of etanercept in Japan
por: Miyasaka, Nobuyuki, et al.
Publicado: (2006)

Infliximab and Etanercept Are Equally Effective in Reducing Enterocyte APOPTOSIS in Experimental Colitis
por: Fries, Walter, et al.
Publicado: (2008)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis
por: Akhlaghi, Saeed, et al.
Publicado: (2019)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia
por: Cordaro, Marika, et al.
Publicado: (2022)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
por: Tanaka, Yoshiya, et al.
Publicado: (2008)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study
por: Tanaka, Yoshiya, et al.
Publicado: (2017)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Longitudinal Analysis of the Use of Etanercept Versus Infliximab Determined From Medical Chart Audit
por: Abarca, Jacob, et al.
Publicado: (2004)

Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases
por: Honda, Suguru, et al.
Publicado: (2019)

Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta
por: Eliesen, Gaby A. M., et al.
Publicado: (2020)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
por: Crnkic, Meliha, et al.
Publicado: (2003)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
por: Akhlaghi, Saeed, et al.
Publicado: (2018)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan
por: Ohno, Shigeaki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uc3l53a3bfu66ojnoc4mhva5fa